Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details 2)

v3.20.2
Stockholders' Equity (Details 2)
9 Months Ended
Sep. 30, 2020
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Total Outstanding | shares 7,469,891
Stock Options, Number Exercisable | shares 5,229,869
Grant Price From 0.26 to 2.02 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.26
Stock Options, Grant Price, Maximum 2.02
Stock Options, Weighted Average Exercise Price $ 0.89
Stock Options, Total Outstanding | shares 3,119,974
Stock Options, Number Exercisable | shares 2,920,807
Stock Options, Weighted Average Remaining Contractual Term 3 years 8 months 23 days
Grant Price From 2.10 to 4.60 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 2.10
Stock Options, Grant Price, Maximum 4.60
Stock Options, Weighted Average Exercise Price $ 2.42
Stock Options, Total Outstanding | shares 3,756,917
Stock Options, Number Exercisable | shares 1,782,041
Stock Options, Weighted Average Remaining Contractual Term 8 years 4 days
Grant Price From 5.30 to 8.86 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 5.30
Stock Options, Grant Price, Maximum 8.86
Stock Options, Weighted Average Exercise Price $ 6.25
Stock Options, Total Outstanding | shares 593,000
Stock Options, Number Exercisable | shares 527,021
Stock Options, Weighted Average Remaining Contractual Term 7 years 7 months 2 days